Navigation Links
Lung Cancer Microscopic Appearance Affects Response to Chemotherapy
Date:2/17/2009

Tumor Structure Should Be Considered in Treating NSCLC, Says Report in "The Oncologist"

DURHAM, N.C., Feb. 17 /PRNewswire/ -- A tumor's cellular structure, or histology, improves treatment decisions that may lead to improved outcomes for patients with non-small cell lung cancer (NSCLC), the most common type of lung cancer, according to a paper in the latest issue of "The Oncologist."

(Logo: http://www.newscom.com/cgi-bin/prnh/20080627/CLF051LOGO )

The findings are based on an analysis of recent studies of the chemotherapy drug pemetrexed to treat NSCLC. "The data confirm that histology matters when treating NSCLC," says Professor Giorgio Scagliotti, M.D., of University of Turin, lead author of the new report.

Prof. Scagliotti and colleagues analyzed data from two recent phase III studies of pemetrexed for NSCLC, which accounts for about 90 percent of all lung cancers. They focused on how differences in cancer histology affect the response to treatment with pemetrexed. The histology of a cancer is its microscopic cellular structure and in NSCLC, tumors may be classified as having a "squamous" or "non-squamous" appearance.

Their analysis showed significant differences in response to pemetrexed between these two lung cancer subtypes. Specifically, pemetrexed was more effective than current forms of chemotherapy against cancers with a non-squamous histology. For these patients, pemetrexed led to significant improvements in overall survival and in survival without progressive cancer. In contrast, for patients whose cancers had the squamous histology, outcomes were similar with or without pemetrexed.

The two studies were a "frontline" trial including patients with previously untreated NSCLC and a "second-line" trial including patients with previous chemotherapy. The interac
'/>"/>

SOURCE AlphaMed Press
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Targeting the protein AEG1 impairs human liver cancer growth in mice
2. Hodgkins Survivors Prone to Breast Cancer Later
3. Social Disconnection in African American Women With Breast Cancer
4. Researchers ID Biomarker for Fatal Prostate Cancer
5. Teens with cancer present unique psychological issues
6. SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Greece & Cyprus
7. New Anti-Clotting Treatment Urged for Cancer Patients
8. Fruit flies soar as lab model, drug screen for the deadliest of human brain cancers
9. Normalizing tumor vessels leaves cancer more benign
10. Womens cancer outcomes improved by surgical evaluation
11. Pediatric Hodgkins disease survivors face increased breast cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... ... September 04, 2015 , ... San Francisco cosmetic dentist ... CEREC is a newer method for creating restorations through innovative imaging equipment and ... the need for multiple appointments, CEREC produces restorations with total precision for a ...
(Date:9/4/2015)... ... ... Many consumers are looking for a quick and convenient way to produce a hot remedy ... Cups provide a quick and simple way to brew a hot cup of cold remedy ... a result, they enhance comfort and health. The invention features a novel design that is ...
(Date:9/4/2015)... ... 04, 2015 , ... The conference program for the upcoming ... 9-10, 2015 at the Diplomat Resort & Spa has been announced and is ... at the top of their field and will be presenting sessions such as ...
(Date:9/4/2015)... ... September 04, 2015 , ... Lalonde Gordon ran a 44.64 ... up with victory in the men’s 400 meters final, with an impressive 44.89 seconds ... Championships in San Jose, Costa Rica in August 2015. The 44.64 time is a ...
(Date:9/4/2015)... ... 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has written an ... Pope’s upcoming trip to the United States. , Yisrayl lays out what he says is ... and society is. Yisrayl also provides the meaning of his own name and describes what ...
Breaking Medicine News(10 mins):Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2
... Thirty-year Communications Veteran Tasked with Expanding Opportunities for ... Breast Cancer Organization, DALLAS, Dec. 12 ... communications professionals, today was named chief marketing,officer for ... largest grassroots,network of breast cancer survivors and activists., ...
... Technologies Inc.,(TSX: NDQ), a developer of real-time ... the operating room, today announced that it ... North American Medical Imaging Product of,the Year ... Novadaq,company executives were recognized during Frost & ...
... Cross volunteer,Krysta Leigh Meinzer is featured in "Cause ... college network, profiling standout student,activists on college campuses ... an episode of the show, which is broadcast ... Think.MTV.com., (Photo: http://www.newscom.com/cgi-bin/prnh/20071212/DC09732 ), ...
... educate that drugs such as morphine are more than just ... -- Many cancer patients endure unnecessary suffering when they resist ... the use of these drugs signifies imminent death, a new ... range of available opioids in order to successfully manage pain ...
... 2007) A new study confirms that chronic kidney ... events in diabetic patients with damage to the large ... drug pioglitazone may help to lower this risk, reports ... , "The data confirm that chronic kidney disease is ...
... Minn. -- When a vaccine to prevent shingles was ... Administration recommended the vaccine for people age 60 and ... the vaccines cost and the perception that shingles primarily ... some physicians undecided about whether healthy adults need the ...
Cached Medicine News:Health News:Susan G. Komen for the Cure Names Tim Doke Chief Marketing Officer 2Health News:Novadaq's SPY Imaging System named Product of the Year by Frost and Sullivan 2Health News:Novadaq's SPY Imaging System named Product of the Year by Frost and Sullivan 3Health News:Novadaq's SPY Imaging System named Product of the Year by Frost and Sullivan 4Health News:Red Cross Blood Donor and Volunteer Featured on mtvU's 'CAUSE EFFECT' 2Health News:Cancer Patients Hold Fast to Belief That Opioids Mean Death 2Health News:Pioglitazone lowers cardiovascular risk in diabetic patients with kidney disease 2Health News:Mayo Clinic article offers data about shingles virus 2
(Date:9/3/2015)... NEW YORK , Sept. 3, 2015 About ... in dryness of eyes due to deficient tear production ... This syndrome is of two types: aqueous tear deficient ... deficient dry eye, lacrimal glands do not produce enough ... eye. Meibomian glands secrete lipids to slow tear evaporation ...
(Date:9/3/2015)... TAMPA, Fla. , Sept. 3, 2015  WellCare ... that Drew Asher , senior vice president and ... Wells Fargo Securities 2015 Healthcare Conference on Wednesday, September ... The presentation will be webcast live. In addition, a ... conclusion of the live broadcast. Both the live broadcast ...
(Date:9/3/2015)... VIEJO, Calif. , Sept. 3, 2015 /PRNewswire/ ... global pharmaceutical company, and AqueSys, Inc. a private ... ocular implants that reduce intraocular pressure (IOP) associated ... into an agreement under which Allergan will acquire ... of the agreement, Allergan will acquire AqueSys for ...
Breaking Medicine Technology:Global Dry Eye Syndrome Market 2015-2019 2Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 2Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 3Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 4Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 5Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 6
... PHILADELPHIA, May 23, 2011 Echo ... Symphony™ tCGM System as a non-invasive, wireless, transdermal ... SkinPrep System for transdermal drug delivery, announced that ... next generation Symphony tCGM System design.  This newly-engineered ...
... 2011 Reportlinker.com announces that a ... in its catalogue: ... The Lymphoma Pipeline: From Research and ... http://www.reportlinker.com/p0507256/A-Decision-Support-Tool-for-Optimizing-The-Lymphoma-Pipeline-From-Research-and-Development-to-Market.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ...
Cached Medicine Technology:Echo Therapeutics Announces Symphony™ tCGM System Progress 2Echo Therapeutics Announces Symphony™ tCGM System Progress 3Reportlinker Adds A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market 2Reportlinker Adds A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market 3Reportlinker Adds A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market 4Reportlinker Adds A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market 5Reportlinker Adds A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market 6Reportlinker Adds A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market 7Reportlinker Adds A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market 8Reportlinker Adds A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market 9Reportlinker Adds A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market 10Reportlinker Adds A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market 11Reportlinker Adds A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market 12Reportlinker Adds A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market 13Reportlinker Adds A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market 14Reportlinker Adds A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market 15Reportlinker Adds A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market 16Reportlinker Adds A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market 17Reportlinker Adds A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market 18Reportlinker Adds A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market 19
... generation access device - XPOSE 4 - ... The XPOSE 4 Device is designed to ... surgery and to easily position and access ... both apical and non-apical placement on the ...
... system is an intuitive, all-in-one endoscopic ... minimize the scarring and risk of ... Incorporating an enhanced, ergonomic handle design ... obstructions, this new device is intended ...
... includes three major components: Blood pump, Cannulae, ... Driver. This system provides partial or total ... conventional therapy, is unable to maintain adequate ... support, blood flows from the natural heart ...
... TISSEEL VH Fibrin Sealant has been shown ... surgical repair. Containing uniform, reproducible concentrations of ... simulates the final stage of the coagulation ... clot that firmly adheres to connective tissue ...
Medicine Products: